SUV varies with time after injection in 18F-FDG PET of breast cancer: Characterization and method to adjust for time differences

Journal of Nuclear Medicine

Volumn 44, Issue 7, 2003, Pages 1044-1050

  Beaulieu, Sylvain ^a   Kinahan, Paul ^a   Tseng, Jeffrey ^a   Dunnwald, Lisa K ^a   Schubert, Erin K ^a   Pham, Pam ^a   Lewellen, Barbara ^a   Mankoff, David A ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

18F FDG; Breast cancer; PET; Standardized uptake value

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOSE TIME EFFECT RELATION; GLUCOSE BLOOD LEVEL; HUMAN; IMAGE ANALYSIS; LINEAR REGRESSION ANALYSIS; MEDICAL INFORMATION; MOLECULAR DYNAMICS; OBSERVER VARIATION; PRIORITY JOURNAL; RADIATION DOSE; STATISTICAL ANALYSIS; STATISTICAL MODEL; ADULT; AGED; BREAST; BREAST TUMOR; EVALUATION; FEASIBILITY STUDY; FEMALE; IMAGE ENHANCEMENT; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MIDDLE AGED; QUALITY CONTROL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STANDARD; TIME; VALIDATION STUDY;

ADULT; AGED; BREAST; BREAST NEOPLASMS; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; METABOLIC CLEARANCE RATE; MIDDLE AGED; QUALITY CONTROL; RADIOPHARMACEUTICALS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0041386217     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Huang SC. Anatomy of SUV Nucl Med Biol 2000;27:643-646.
2. Keyes JW. SUV. standard uptake or silly useless value? J Nucl Med. 1995;36:1836-1839.
3. Delbeke D, Rose DM, Chapman WC, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med. 1999;40:1784-1791.
4. Watanabe H, Sbinozaki T, Aoki J, et al Glucose metabolic analysis of musculoskeletal tumors using nuorine-18-FDG PET as an aid in preoperative planning. J Bone Joint Surg [Br]. 2000;82:760-767.
5. 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer. 1998; 82:1664-1671.
6. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-1695.
7. Hamburg LM, Hunter GT, Albert NM, et al. The dose uptake ratio as an index of glucose metabolism useful parameter or oversimplification? J Nucl Med. 1994;35:1308-1312.
8. Thie JA, Hubner KF, Smith GT. Optimizing imaging time for improved performance in oncology PET studies. Mol Imaging Biol. 2002;4:238-244.
9. Mankoff DA, Dunwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43:500-509.
10. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1988;29:241-247.
11. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE. Performance characteristics of a whole body PET scanner. J Nucl Med. 1994;35:1398-1406.
12. Lewellen TK, Kohlmeyer S, Miyaoka R, Schubert S. Steams C. Investigation of the count rate performance of the General Electric Advance positron emission tomograph. IEEE Trans Nucl Sci. 1995;42:1051-1057.
13. Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med. 1998;39:250-254.
14. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26:1345-1348.
15. 15F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871-875.